Aurinia Pharmaceuticals Inc (AUPH) Rating Reiterated by HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in a report published on Wednesday morning. They currently have a $12.00 target price on the biotechnology company’s stock.
A number of other analysts have also issued reports on the company. Zacks Investment Research lowered Aurinia Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, October 24th. BidaskClub lowered Aurinia Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, July 28th. Cantor Fitzgerald reaffirmed a buy rating and issued a $14.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. Leerink Swann lifted their price target on Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an outperform rating in a research note on Monday, October 23rd. Finally, Seaport Global Securities reaffirmed a buy rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $10.79.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.14 on Wednesday. Aurinia Pharmaceuticals has a 12 month low of $2.02 and a 12 month high of $10.54.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. Aurinia Pharmaceuticals had a negative return on equity of 27.47% and a negative net margin of 18,089.02%. The firm’s revenue was up .0% compared to the same quarter last year. analysts predict that Aurinia Pharmaceuticals will post -1.01 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/18/aurinia-pharmaceuticals-inc-auph-rating-reiterated-by-hc-wainwright.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AUPH. Royal Bank of Canada boosted its stake in Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after buying an additional 1,341 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Aurinia Pharmaceuticals by 13,197.5% during the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after buying an additional 26,395 shares during the last quarter. Investment Centers of America Inc. acquired a new position in Aurinia Pharmaceuticals during the second quarter worth $184,000. Cutler Capital Management LLC acquired a new position in Aurinia Pharmaceuticals during the second quarter worth $184,000. Finally, Kazazian Asset Management LLC boosted its stake in Aurinia Pharmaceuticals by 47.3% during the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock worth $406,000 after buying an additional 21,304 shares during the last quarter. 27.74% of the stock is currently owned by institutional investors.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.